Developing enduring infrastructure to efficiently evaluate treatments for patients with Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
MYELO-CAN
MYELO-CAN
Developing enduring infrastructure to efficiently evaluate treatments for patients with Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
A Randomized Control Trial Platform
MYELO-CAN is a trial platform designed by patients and clinicians, whose priority is to improve patient-prioritized outcomes for those affected by myelodysplastic syndrome and acute leukemia.
There are currently two ongoing trials:
1. Tranexamic acid (TXA) trial: enrollment started Sept 2025
2. Antibiotic prophylaxis (ABX) trial: anticipated start Mar 2026
The Platform Trial
MYELO-CAN Platform
Sub-Studies
01
Tranexamic
Acid (TXA) Trial
Enrolling as of Sept 2025
02
Antibiotic
Prophylaxis
(ABX) Trial
Anticipated start Mar 2026
MYELO-CAN Participating sites
